AstraZeneca divestment of Movantik to RedHill Biopharma completed Medical Dialogues Bureau4 April 2020 5:30 AM GMTUK: AstraZeneca has completed the previously communicated agreement to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada,...
AstraZeneca Lokelma recommended for approval in EU for patients with hyperkalaemia on stable haemodialysis Medical Dialogues Bureau31 March 2020 7:35 AM GMTLokelma is a highly selective, oral potassium-removing agent currently approved in the US, EU, Canada, Hong Kong, China, Russia, and Japan for the...
Cipla gets USFDA final nod for Esomeprazole ANDA for Oral Suspension Medical Dialogues Bureau27 March 2020 7:21 AM GMTCipla's Esomeprazole for Oral Suspension 10mg, 20mg and 40mg is an AB-rated generic therapeutic equivalent version of AstraZeneca Pharmaceutical's ...
AstraZeneca gets orphan drug designation for pancreatic cancer drug Lynparza Medical Dialogues Bureau24 March 2020 6:00 AM GMTUK: AstraZeneca has announced that Lynparza (olaparib) has been granted orphan drug designation (ODD) in Japan for the maintenance treatment of...
AstraZeneca's Phase III CASPIAN trial final analysis shows Imfinzi confirmed survival benefit for small cell lung cancer patients Medical Dialogues Bureau21 March 2020 3:30 AM GMTImfinzi confirmed a sustained overall survival benefit in the final analysis of the Phase III CASPIAN trial in 1st-line extensive-stage small cell...
AstraZeneca Pharma India gets DCGI nod for Calquence-Acalabrutinib 100mg capsules Medical Dialogues Bureau14 March 2020 6:33 AM GMTAcalabrutinib 100mg capsules are indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL).
AstraZeneca fails to meet target endpoints in Phase II bladder cancer trial Medical Dialogues Bureau10 March 2020 4:00 AM GMTUSA: The Phase III DANUBE trial for Imfinzi (durvalumab) and Imfinzi plus tremelimumab in unresectable, Stage IV (metastatic) bladder cancer did not...
AstraZeneca to sublicense global rights to Movantik Medical Dialogues Bureau28 Feb 2020 3:30 AM GMTMovantik is a once-daily oral PAMORA approved by the US Food and Drug Administration for the treatment of OIC in adult patients with chronic...
AstraZeneca leukemia drug Calquence gets USFDA okay Medical Dialogues Bureau24 Nov 2019 4:30 AM GMTNew Delhi: AstraZeneca said late on Thursday that the U.S. Food and Drug Administration (FDA) had given its go-ahead for the company's Calquence drug...
BeiGene gets USFDA approval for lymphoma drug Brukinsa Medical Dialogues Bureau17 Nov 2019 3:50 AM GMTBeiGene tested the treatment, Brukinsa, in 118 patients with mantle cell lymphoma enrolled in two studies. About three-quarters were Asian, 21%...
AstraZeneca CKD anaemia drug Roxadustat shows increased haemoglobin levels in Phase 3 trial Medical Dialogues Bureau9 Nov 2019 3:45 AM GMTNew Delhi: AstraZeneca recently presented detailed results from the Phase III OLYMPUS and ROCKIES trials showing that Roxadustat significantly...
AstraZeneca sells European rights for schizophrenia drug Seroquel, Seroquel XR for USD 178 million Farhat Nasim30 Oct 2019 11:55 AM GMTThe treatment, Seroquel, and another version, Seroquel XR, have lost patent protection in Europe and Russia, AstraZeneca said. The drug variants are...